INCR InterCure Ltd.
USHealthcareAs of 2026-07-10 16:00
Why INCR matters now
InterCure Ltd. (INCR) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.97 with -1.02% on the session and $55.4M in market capitalization; recent performance reads 1-month +9.26% and YTD +2.06%.
The latest financial table shown here is FY 2025, with revenue of $270.2M, net income of $-35.7M, and EPS of $-0.63. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield 5.8%.
The latest indexable market news headline is "InterCure Secures NIS 22 Million in Private Placement Financing Led by Leading Pharma-Focused Hedge Funds" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $—; recent insider activity includes Rabinovich Alexander filing . These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.39
P/S
0.83
EV/EBITDA
-8.96
DCF Value
$-3.51
FCF Yield
5.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
21.7%
Operating Margin
-17.8%
Net Margin
-19.5%
ROE
-8.8%
ROA
-5.3%
ROIC
-4.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| FY 2025 | $270.2M | $-35.7M | $-0.63 |
| Q2 2025 | $65.0M | $-852.0K | $-0.02 |
| Q1 2025 | $65.0M | $-852.0K | $-0.02 |
| Q4 2024 | $56.6M | $-34.6M | $-0.79 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
IL
Exchange
—
Beta
0.57
InterCure Ltd., including its subsidiaries, is actively involved in the entire lifecycle of medical cannabis products. This encompasses everything from initial research and cultivation to manufacturing, marketing, and global distribution, serving both the Israeli market and international territories. The company's offerings feature dried cannabis flower alongside cannabis extracts infused with oil. Beyond its core cannabis operations, InterCure also directs investments towards the biomedical sector. Founded in 1994, the firm's main offices are located in Herzliya, Israel.